Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia

Keyphrases

• Malaria 100%
• African Region 100%
• Hydroxyurea 100%
• Sickle Cell Anemia 100%
• Zero Harm 100%
• Placebo 50%
• Sub-Saharan Africa 16%
• Adverse Events 16%
• Hydroxyurea Therapy 16%
• Malaria Incidence 16%
• Africa 8%
• Clinical Efficacy 8%
• Leukocytes 8%
• Sickle Cell Disease 8%
• Dose-limiting Toxicity 8%
• Uganda 8%
• Sepsis 8%
• Fetal Hemoglobin 8%
• Placebo-controlled Trial 8%
• Severe Malaria 8%
• In Vitro Study 8%
• Clinical Effect 8%
• Blood Transfusion 8%
• Neutropenia 8%
• Confidence Interval 8%
• Incidence Rate 8%
• Hemoglobin Concentration 8%
• Hematotoxicity 8%
• Reticulocytes 8%
• Optimal Dosing 8%
• Acute Chest Syndrome 8%
• Vaso-occlusive 8%
• Serious Adverse Events 8%
• Clinical Malaria 8%
• Infection Events 8%
• Malaria Infection 8%
• Laboratory Effects 8%
• Splenic Sequestration 8%
• Dactylitis 8%
• Event Effect 8%
• Optimal Monitoring 8%
• Malaria Severity 8%
• Pain Crisis 8%
• Clinical Outcomes 8%
• Free Region 8%
• Cellular Burden 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Hydroxycarbamide 100%
• Sickle Cell Anemia 100%
• Placebo 50%
• Infection 21%
• Adverse Event 21%
• Acute Chest Syndrome 7%
• Dactylitis 7%
• Hemoglobin F 7%
• Sepsis 7%
• Neutropenia 7%